JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (NCT06108050)

🧪 Interventions in This Study

• JZP898 (DRUG)
• Pembrolizumab (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Adult ≥ 18 years of age
2. Histological or cytological diagnosis of advanced or metastatic solid tumor.
3. Previously treated participants with solid tumors that are amenable to CPI therapy (eg. NSCLC, melanoma, HNSCC, RCC, HCC, gastroesophageal carcinomas, UC, or CRC \[MSI-H\]) for whom, in the opinion of the investigator, there is no SoC available to convey clinical benefit.
4. Parts A2 and B: previously-treated (≥ 1 line of prior anticancer therapy) participants with select tumor types (NSCLC, HNSCC, melanomas, RCC, and UC) who have progressed on/after prior CPI therapy based on investigator assessment per RECIST version 1.1.
5. Participants in select tumor types:
6. NSCLC: eligible for platinum-based therapy and received platinum-based therapy prior to inclusion in the study.
7. HNSCC: eligible for platinum therapy and received platinum-based therapy prior to inclusion in this study.
8. Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.
9. ECOG score of 0 to 1.
10. Measurable disease per RECIST version 1.1 criteria.
11. Parts A1 and A2 only: willing to consent to mandatory tumor biopsies (both pretreatment and post-treatment with JZP898) unless medically infeasible
12. Adequate organ and bone marrow function as indicated by the following laboratory values (within 4 weeks prior to starting the study interventions)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (10 Sites)

• California Cancer Associates for Research and Excellence — Encinitas, California
• California Cancer Associates for Research and Excellence — Fresno, California
• Sarah Cannon Research Institute at HealthONE — Denver, Colorado
• Florida Cancer Specialists — Orlando, Florida
• Duke University Medical Center - Duke Cancer Institute — Durham, North Carolina
• Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
• SCRI Oncology Partners — Nashville, Tennessee
• Texas Oncology - Baylor Charles A Sammons Cancer Center — Dallas, Texas
• The University of Texas MD Anderson Cancer Center — Houston, Texas
• Virginia Cancer Specialists — Fairfax, Virginia

📞 Contact the Study Coordinator

Phone: (215) 832-3750

Email: ClinicalTrialDisclosure@JazzPharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Solid Tumor

• Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors — San Antonio, Texas
• Study in Advanced Solid Tumor Patients — Boston, Massachusetts
• Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors — La Jolla, California
• A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors — Los Angeles, California
• Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa

Explore by condition: All Advanced Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.